These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 7885370)

  • 21. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
    Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
    Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Liver injury under tuberculostatic treatment].
    Fattinger K; Braunschweig S; Reichen J; Meier-Abt PJ; Krähenbühl S
    Praxis (Bern 1994); 1997 Apr; 86(15):626-9. PubMed ID: 9213916
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
    Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
    Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
    Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up.
    Su WJ; Perng RP
    Int J Tuberc Lung Dis; 2002 Nov; 6(11):1029-32. PubMed ID: 12475151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy.
    Hong Kong Chest Service/British Medical Research Council
    Am Rev Respir Dis; 1989 Dec; 140(6):1618-22. PubMed ID: 2604291
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Treatment of tuberculosis. Drug combinations, therapeutic problems and results in a 10-year case load].
    Morland L
    Tidsskr Nor Laegeforen; 1990 Nov; 110(28):3608-11. PubMed ID: 2260057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Short-term therapy of lung tuberculosis using a fixed combination of isoniazid, rifampicin and pyrazinamide. Results after 2 years].
    Brändli O; Haegi V; Villiger B; Bohn W; Baumann HR; Zäch R
    Schweiz Med Wochenschr; 1989 Mar; 119(10):299-305. PubMed ID: 2652281
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Directly observed treatment for tuberculosis in a Buenos Aires City hospital].
    González C; Sáenz C; Herrmann E; Jajati M; Kaplan P; Monzón D
    Medicina (B Aires); 2012; 72(5):371-9. PubMed ID: 23089112
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [The effectiveness of pyrazinamide-containing six-month short course chemotherapy].
    Wada M
    Kekkaku; 2000 Nov; 75(11):665-73. PubMed ID: 11140090
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of a non-rifampicin continuation phase (6HE) following thrice-weekly intensive phase for the treatment of new sputum positive pulmonary tuberculosis.
    Indian J Tuberc; 2007 Apr; 54(2):84-90. PubMed ID: 17575680
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cutaneous reaction after pyrazinamide initiation].
    Mulliez P; Mbassi Fouda FL; Roy Saint-Georges F
    Med Mal Infect; 2011 Sep; 41(9):499-500. PubMed ID: 21458177
    [No Abstract]   [Full Text] [Related]  

  • 33. A case of thrombocytopenia caused by rifampicin and pyrazinamide.
    Bansal R; Sharma PK; Sharma A
    Indian J Pharmacol; 2013; 45(4):405-7. PubMed ID: 24014922
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic effects of drug interaction in tuberculosis patients and their fate.
    Jaju M; Jaju M; Ahuja YR
    Teratog Carcinog Mutagen; 1984; 4(3):261-72. PubMed ID: 6205465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Split-drug regimens for the treatment of patients with sputum smear-positive pulmonary tuberculosis--a unique approach.
    Santha T; Rehman F; Mitchison DA; Sarma GR; Reetha AM; Prabhaker R;
    Trop Med Int Health; 2004 May; 9(5):551-8. PubMed ID: 15117298
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Assessment of the use of a multicomponent drug in the treatment of new cases of pulmonary tuberculosis].
    Semenova OV
    Probl Tuberk Bolezn Legk; 2003; (11):22-5. PubMed ID: 14689793
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate.
    Chang KC; Leung CC
    Clin Infect Dis; 2010 Aug; 51(3):366-7; author reply 367-8. PubMed ID: 20597681
    [No Abstract]   [Full Text] [Related]  

  • 38. Unilateral and painless development of isoniazid induced gynecomastia during re-treatment of pulmonary tuberculosis.
    Kumar L; Gupta R; Puri MM; Jaiswal A; Srinath ; Murar A; Behera D
    J Assoc Physicians India; 2011 Nov; 59():733-5. PubMed ID: 22616343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.
    Jawahar MS; Rajaram K; Sivasubramanian S; Paramasivan CN; Chandrasekar K; Kamaludeen MN; Thirithuvathas AJ; Ananthalakshmi V; Prabhakar R
    Trop Med Int Health; 2005 Nov; 10(11):1090-8. PubMed ID: 16262733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Fulminant hepatic failure due to tuberculostatic drugs: case report].
    Malla I; Fauda M; Casanueva E; Fernández MI; Amante M; Cheang Y; Giacove G; Pedreira A; Petracca P; González Campaña A; Silva M; Podestá G
    Arch Argent Pediatr; 2012; 110(3):e35-8. PubMed ID: 22760756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.